Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

International, Randomized, Open Label Study to Compare the Safety and Efficacy of Lixisenatide vs. Sulfonylurea on Top of Basal Insulin Treatment in Type 2 Diabetes Mellitus Subjects Who Elect to Fast During Ramadan

Next Previous
X
Search
Trial Profile

International, Randomized, Open Label Study to Compare the Safety and Efficacy of Lixisenatide vs. Sulfonylurea on Top of Basal Insulin Treatment in Type 2 Diabetes Mellitus Subjects Who Elect to Fast During Ramadan

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 05 Nov 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Lixisenatide (Primary) ; Insulin; Metformin; Sulfonylureas
  • Indications Type 2 diabetes mellitus
  • Focus Adverse reactions
  • Acronyms LixiRam
  • Sponsors Sanofi

    • Most Recent Events

    • 05 Oct 2018 Results presented at the 54th Annual Meeting of the European Association for the Study of Diabetes
    • 20 Sep 2017 Status changed from active, no longer recruiting to completed.
    • 21 Jun 2017 Planned End Date changed from 30 Sep 2017 to 24 Jul 2017.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top